Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
Public ClinicalTrials.gov record NCT00307125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies Will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection
Study identification
- NCT ID
- NCT00307125
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 757 participants
Conditions and interventions
Conditions
Interventions
- Rituximab plus immunosuppression Drug
- Placebo plus immunosuppression Drug
Drug
Eligibility (public fields only)
- Age range
- 5 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2006
- Primary completion
- Nov 30, 2012
- Completion
- Nov 30, 2012
- Last update posted
- Mar 22, 2015
2006 – 2012
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama, Pediatric Nephrology | Birmingham | Alabama | 35294 | — |
| University of Alabama | Birmingham | Alabama | 35294 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| University of Florida | Gainesville | Florida | 32601 | — |
| University of Illinois | Chicago | Illinois | 60607 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
| Children's Hospital Boston | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Saint Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| Legacy Transplant Services | Portland | Oregon | 97210 | — |
| Oregon Health Science University | Portland | Oregon | 97219 | — |
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | 19104 | — |
| The Methodist Hospital | Houston | Texas | 77030 | — |
| Children's Hospital and Regional Medical Center | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00307125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2015 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00307125 live on ClinicalTrials.gov.